A new phase 2 clinical trial shows that the drug baxdrostat may help fight treatment-resistant hypertension. The drug is a small molecule inhibitor of aldosterone synthase. In the trial, patients took baxdrostat once a day and experienced an 11 mmHg reduction in systolic blood pressure. The medicine had no side effects and had no influence on cortisol levels.
Phase 3 clinical trial
Baxdrostat is a first-in-class drug that may provide hope for people who have failed to respond to conventional treatment for hypertension. High blood pressure is a leading cause of strokes, heart attacks, kidney failure, and other serious health complications. Unfortunately, there is no known cause for high blood pressure, and most patients must take lifelong medication to treat it.
The drug Baxdrostat has shown promising results in a phase-three clinical trial in which it reduced blood pressure significantly. It targets a hormone in the body that controls the amount of salt in the body. Patients who participated in the trial saw their blood pressure fall as much as 20 points on average. But even those who took lower dosages still saw a reduction.
The study also showed that baxdrostat had minimal side effects. The medication was well-accepted and had no noticeable side effects despite having a mild diuretic impact. Symptoms were generally mild and reported in just a small number of patients.
The drug has some side effects, but they are minimal in comparison to the negative effects of currently available medications. It has an acceptable safety profile, and it can be added to other medications to treat treatment-resistant hypertension. However, the drug’s approval is not guaranteed, and a phase 3 clinical trial may be necessary. This trial is expected to last 12 to 18 months.
The drug works by blocking the production of aldosterone, a hormone that regulates salt in the body. It is believed that the hormone is partially responsible for the resistance to traditional treatments for hypertension. In the phase 3 trial, 274 people with hypertension who had failed to respond to previous treatments were given varying doses of Baxdrostat for 12 weeks.
Currently available drugs such as beta-blockers and diuretics are not effective in patients with resistant hypertension. However, new drugs may be able to target a new target. The drug may be an alternative to ACE inhibitors and may be a better option for people with uncontrolled hypertension.
Mechanism of action
Baxdrostat is an oral small-molecule inhibitor of aldosterone synthase (AS). It is an effective treatment for hypertension in patients who are resistant to other medications. It has an enhanced safety profile and a differentiated mechanism of action.
Baxdrostat works by inhibiting aldosterone synthase, which is involved in the production of aldosterone by the adrenal gland. It is designed to reduce blood pressure in patients with hypertension or primary aldosteronism, both of which are caused by abnormalities of the aldosterone system. However, this drug may increase the risk of cardiovascular disease, stroke, and kidney disease.
This drug selectively targets aldosterone synthase, an enzyme encoded by the CYP11B2 gene. It has a low affinity for another enzyme, 11ss-hydroxylase, which is involved in the production of cortisol. In a clinical study, baxdrostat reduced plasma levels of aldosterone but did not alter cortisol levels.
Baxdrostat has a promising future in treatment-resistant hypertension. A study involving people with high blood pressure, it reduced systolic blood pressure by 12 weeks and significantly reduced diastolic blood pressure. The drug is currently the only drug on the market with these properties.
Baxdrostat reduces the production of aldosterone, a hormone that regulates the level of salt in the blood. This drug suppresses the aldosterone hormone in the body, causing a significant drop in blood pressure in hypertensive patients. As a result, patients with hypertension respond well to Baxdrostat.
Baxdrostat is a selective and competitive inhibitor of aldosterone synthase, a key enzyme involved in the production of cortisol and aldosterone. In preclinical studies, baxdrostat decreased aldosterone levels without affecting cortisol levels. However, it is unclear how long baxdrostat can suppress aldosterone levels.
During clinical trials, baxdrostat was generally well tolerated, with few adverse events reported. However, there were some cases of potassium elevation and hyponatremia. Of these cases, only two patients required hospitalization, and all recovered well enough to resume baxdrostat.
After a five-day run-in period, patients received the experimental drug for 15 days. After that, patients were enrolled in a study to determine whether the drug caused any side effects. The trial included a screening period of up to 28 days, a five-day run-in period, a controlled diet, and baseline PD assessments.
In clinical trials, baxdrostat has been found to reduce systolic blood pressure in patients with treatment-resistant hypertension. The study involved 248 patients with blood pressure over 130/80 mm Hg, and they had been taking at least one antihypertensive medication and a diuretic. The study was placebo-controlled and included patients from multiple clinical locations.
The drug works by suppressing the production of aldosterone, a hormone essential for the regulation of salt in the body. This can reduce the levels of aldosterone in the blood and urine. This drug may cause a significant drop in blood pressure in patients with hypertension, as excess aldosterone is a contributor to hypertension.
Researchers have completed enrollment for the Phase 2 HALO trial, a trial in people with uncontrolled hypertension. The study is expected to finish in the second half of 2022. In addition, the company has initiated a phase 2 open-label extension study to assess the drug’s safety and tolerability over a longer period of time.
Aldosterone synthase is inhibited by the small molecule medication baxdrostat, which is taken orally. It has a high therapeutic index and has shown promising results in clinical trials.
During its clinical trial, baxdrostat was well tolerated. There were no reported serious side effects. However, there were some cases of hyponatremia and raised potassium levels. Hyperkalemia was noted in six patients. Three of them had potassium levels that were 6.0 to 6.3 mmol/L, while the other two patients had higher levels. Fortunately, all of these patients were able to resume baxdrostat and completed the study.
Baxdrostat is an oral medication that can help millions of people manage their hypertension. It works by blocking a hormone in the body that regulates blood salt levels. This can reduce blood pressure and potentially prevent strokes and heart attacks. The drug has been studied in people with treatment-resistant hypertension.
In the bright trial, baxdrostat significantly reduced systolic and diastolic blood pressure. At the AHA 2022 conference in Chicago, the researchers revealed the trial’s findings, and they were also simultaneously published in the New England Journal of Medicine. The study enrolled 248 patients with a systolic blood pressure of 130/80 mmHg or higher to receive baxdrostat or a placebo. Patients were randomly assigned to receive one of the three active baxdrostat dosages or a placebo.. The primary endpoint was the change in systolic blood pressure over 12 weeks.
Baxdrostat is an aldosterone synthase inhibitor, which reduces high blood pressure. It reduces serum and urinary aldosterone levels and increases the activity of plasma renin. In patients with treatment-resistant hypertension, baxdrostat may be a promising treatment option.
Although the early-phase clinical and preclinical profiles of baxdrostat are favorable, it is still important to examine its safety in the setting of long-term use. It is necessary to ascertain its mechanism of action and steady-state effects. The safety of baxdrostat is dependent upon its efficacy and safe dosing.